{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-045729","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.922904+00:00","generated_at":"2026-05-24T03:52:52.056843+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CalciMedica reports FY2024 net loss $13.7M; cash $18.7M, funding into mid-2026","bullets":["Net loss $13.7M in 2024 (vs $34.4M in 2023); R&D $14.5M, G&A $9.7M.","Cash $18.7M at Dec 31, 2024; plus $9.7M net from March 2025 debt facility; runway into mid-2026.","Phase 2 KOURAGE trial in AKI enrolling; data expected around end of 2025.","Post-hoc CARDEA analysis: 62.7% relative mortality reduction in AKI patients at day 30.","End-of-Phase 2 FDA meeting for acute pancreatitis program planned for mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-045729","json":"https://secwatch.observer/filing/0000950170-25-045729.json","markdown":"https://secwatch.observer/filing/0000950170-25-045729.md","text":"https://secwatch.observer/filing/0000950170-25-045729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000095017025045729/0000950170-25-045729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000095017025045729/ck0001534133-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:52:52.056843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}